Show simple item record

dc.contributor.authorDosunmu, Yewande*
dc.contributor.authorOwusu-Apenten, Richard K.*
dc.date.accessioned2019-03-04T13:57:27Z
dc.date.available2019-03-04T13:57:27Z
dc.date.issued2017-10-28
dc.identifier.citationDosunmu, Y. & Owusu-Apenten, R. (2017). Effects of Ascorbic Acid, Dehydroascorbic Acid and Methotrexate on Breast Cancer Cell Viability. Journal of Applied Life Sciences International, 14 (2),
dc.identifier.doi10.9734/JALSI/2017/37185
dc.identifier.urihttp://hdl.handle.net/10034/621939
dc.description.abstractAims: To examine the effects of ascorbic acid (AA), dehydroascorbic acid (DHA) and methotrexate (MTX) combined treatments on (MDA-MB-231) breast cancer cell viability and intracellular reactive oxygen species (ROS). Study Design: In-vitro method. Place and Duration of Study: Biomedical Sciences Research Institute, University of Ulster, Coleraine, BT52 1SA, United Kingdom. September 2016-2017 Methodology: Cytotoxicity tests were performed with MTX (0.01- 1000 µmol/l) alone or in combination with AA or DHA, for 72 h. Cell viability was measured by 3-4,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide (MTT) or Sulforhodamine B (SRB) assays. Intracellular ROS was measured by 2’,7’-dichlorofluroscein diacetate assay. Results: Treatments of MDA-MB231 cells with single agents, showed dose dependent response with 50% inhibition of cell viability (IC50) of 110.5-201.4 µmol/l (MTX), 2237-5703 µmol/l (AA) or 2474 µmol/l (DHA). Combination studies showed clear synergisms for MTX (~10 µmol/l) and DHA or AA (1100 µmol/l) but weak or no interactions at other concentrations. Three days combination treatment of DHA showed decrease of ROS, which was reversed by MTX (>10 µmol/l). Conclusions: Co-treatment of methotrexate with AA or DHA showed synergism (C1<1.0) and enhanced cytotoxicity of the anti-folate towards MDA-MB-231 breast cancer cells. Intracellular ROS decreased with AA and DHA treatment, which might be useful for reducing MTX-related oxidative stress.
dc.language.isoenen
dc.publisherSCIENCEDOMAIN Internationalen_US
dc.relation.urlhttp://www.sciencedomain.org/abstract/21618en_US
dc.rightsAttribution-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/en_US
dc.subjectAscorbic aciden_US
dc.subjectdehydroascorbic aciden_US
dc.subjectmethotrexateen_US
dc.subjectbreast canceren_US
dc.subjectMDA-MB-231 cellsen_US
dc.subjectReactive oxygen speciesen_US
dc.titleEffects of ascorbic acid, dehydroascorbic acid and methotrexate on breast cancer cell viability.en_US
dc.typeArticleen_US
dc.identifier.eissn2394-1103
dc.contributor.departmentUniversity of Chester, University of Ulster
dc.identifier.journalJournal of Applied Life Sciences Internationalen_US
dc.date.accepted2017-10-24
or.grant.openaccessYesen_US
rioxxterms.funderNAen_US
rioxxterms.identifier.projectNAen_US
rioxxterms.versionVoRen_US
rioxxterms.licenseref.startdate2017-10-28


Files in this item

Thumbnail
Name:
Apenten1422017JALSI37185.pdf
Size:
1020.Kb
Format:
PDF
Request:
Main article

This item appears in the following Collection(s)

Show simple item record

Attribution-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NoDerivatives 4.0 International